Healthpeak Properties（DOC）株式概要
ヘルスピーク・プロパティーズは総合不動産投資信託（REIT）であり、S&P500にランクインしている。 詳細
DOC Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Healthpeak Properties, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$20.51 |
| 52週高値 | US$22.95 |
| 52週安値 | US$15.70 |
| ベータ | 1.0 |
| 1ヶ月の変化 | -5.27% |
| 3ヶ月変化 | 4.91% |
| 1年変化 | 20.65% |
| 3年間の変化 | 0.89% |
| 5年間の変化 | -42.52% |
| IPOからの変化 | 286.07% |
最新ニュース
ナラティブ更新 • Aug 07
DOC: Higher 2026 Outlook And JV Will Mask Deepening Margin Pressure
Analysts have raised their price target for Healthpeak Properties from $17.00 to about $17.71. The updated target reflects revised assumptions that incorporate a slightly higher discount rate, more conservative expectations for revenue and profit margins, and a significantly higher projected future P/E multiple.Seeking Alpha • Aug 05
Healthpeak Properties: A Well-Covered 5.6% Yield, But Life Science Recovery Remains Key
Summary Healthpeak Properties remains in growth mode, supported by a well-covered 5.6% dividend yield and low leverage at 4.7x net debt/EBITDAre. Janus Living, DOC’s senior housing spin-off, is delivering strong results and materially contributes to DOC’s market cap and growth outlook. Lab segment occupancy is improving, signaling a potential inflection in the life science sector, though this comes with elevated capital expenditures. Dividend coverage remains robust, with a payout ratio of 70–80%, and management has authorized a $500 million share repurchase program. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 24
DOC: Brookfield Venture And Index Additions Will Support Future Upside
Analysts have raised their price target on Healthpeak Properties to $27.22 from $26.94. This change reflects revised assumptions about fair value, discount rate, revenue growth, profit margins, and future P/E levels.Recent updates
ナラティブ更新 • Aug 07
DOC: Higher 2026 Outlook And JV Will Mask Deepening Margin Pressure
Analysts have raised their price target for Healthpeak Properties from $17.00 to about $17.71. The updated target reflects revised assumptions that incorporate a slightly higher discount rate, more conservative expectations for revenue and profit margins, and a significantly higher projected future P/E multiple.Seeking Alpha • Aug 05
Healthpeak Properties: A Well-Covered 5.6% Yield, But Life Science Recovery Remains Key
Summary Healthpeak Properties remains in growth mode, supported by a well-covered 5.6% dividend yield and low leverage at 4.7x net debt/EBITDAre. Janus Living, DOC’s senior housing spin-off, is delivering strong results and materially contributes to DOC’s market cap and growth outlook. Lab segment occupancy is improving, signaling a potential inflection in the life science sector, though this comes with elevated capital expenditures. Dividend coverage remains robust, with a payout ratio of 70–80%, and management has authorized a $500 million share repurchase program. Read the full article on Seeking Alphaナラティブ更新 • Jul 24
DOC: Brookfield Venture And Index Additions Will Support Future Upside
Analysts have raised their price target on Healthpeak Properties to $27.22 from $26.94. This change reflects revised assumptions about fair value, discount rate, revenue growth, profit margins, and future P/E levels.ナラティブ更新 • Jul 10
DOC: Index Additions And Higher Earnings Outlook Will Support Future Upside
Analysts have raised their price target for Healthpeak Properties from $25.80 to $26.94, citing updated assumptions around revenue growth, profit margins, discount rates, and future P/E expectations. What’s in the News for Healthpeak Properties Healthpeak Properties, Inc.
ナラティブ更新 • Jun 26
DOC: Buybacks And Raised Earnings Guidance Will Support Measured Future Upside Potential
Analysts have slightly increased their price target on Healthpeak Properties to $21.44 from $20.83, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News for Healthpeak Properties Healthpeak Properties reported a share repurchase activity from January 1, 2026 to May 5, 2026, buying back 5,950,000 shares for US$100 million, representing 0.86% of its shares, according to a buyback tranche update.ナラティブ更新 • Jun 12
DOC: Raised 2026 Outlook And Buybacks Will Conceal Mounting Margin Risks
Analysts have adjusted their price target on Healthpeak Properties from $16.00 to $17.00, tying the change to updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Healthpeak Properties reported first quarter 2026 funds from operations as adjusted (FFOA) of $0.45 per share, which was above analyst estimates, supported by steady leasing momentum.ナラティブ更新 • May 29
DOC: Buybacks And Higher Earnings Guidance Will Support Measured Future Upside Potential
Analysts have nudged their price target for Healthpeak Properties from about $20.17 to roughly $20.83, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Healthpeak Properties reported repurchasing 5,950,000 shares for US$100 million between January 1, 2026 and May 5, 2026, representing 0.86% of its shares under the ongoing buyback program announced on July 25, 2024 (Key Developments).ナラティブ更新 • May 13
DOC: Buyback Activity And Raised Earnings Outlook Will Mask Weaker Margin Outlook
Analysts have kept their $16.00 price target on Healthpeak Properties unchanged, citing updated assumptions that include a slightly higher discount rate, a shift to declining revenue growth, lower profit margins, and a much higher future P/E estimate. What's in the News From January 1, 2026 to May 5, 2026, Healthpeak Properties repurchased 5,950,000 shares, representing 0.86% of its stock for US$100 million under its existing buyback program (Key Developments).ナラティブ更新 • Apr 28
DOC: Higher Margins And Earnings Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties by about $0.64 to $25.80 as updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E are incorporated into their models. What's in the News Healthpeak Properties reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares for $0 million under its existing buyback program, closing out a total repurchase of 5,091,156 shares, or 0.73%, for $94.17 million under the authorization announced on July 25, 2024 (Key Developments).ナラティブ更新 • Apr 14
DOC: Share Repurchases And Improved Margins Will Support Future Upside Potential
Analysts have slightly raised their price target on Healthpeak Properties to about $26.44, a marginal change from roughly $26.43. The revision reflects updated assumptions related to discount rate, revenue growth, profit margin and a projected future P/E near 98x.ナラティブ更新 • Mar 31
DOC: Earnings Guidance And Completed Buyback Will Shape Measured Future Return Potential
Analysts now hold their $16.00 price target on Healthpeak Properties while adjusting underlying assumptions slightly on discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning rather than a major shift in their view of the stock.ナラティブ更新 • Mar 16
DOC: Share Repurchases And Stronger Margins Will Support Future Upside Potential
Analysts now estimate Healthpeak Properties' fair value price target at about $26.43, compared with the previous estimate of roughly $26.71. The revision reflects updated views on revenue growth, profit margin and future P/E assumptions.ナラティブ更新 • Mar 02
DOC: Earnings Outlook And Completed Buyback Will Highlight Limited Future Upside
Analysts have maintained their $16.00 price target for Healthpeak Properties. They cite only small adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E that together do not materially change their view of the stock’s valuation.ナラティブ更新 • Feb 16
DOC: Share Buyback Completion And Earnings Outlook Will Shape Fair Prospects
Analysts have adjusted their price target on Healthpeak Properties from $18.00 to $16.00. The revision reflects updated models that incorporate a slightly higher discount rate, a lower profit margin assumption and a revised future P/E estimate, while also taking into account a higher revenue growth outlook.ナラティブ更新 • Feb 02
DOC: Stable Margins And Modest Assumption Shifts Will Support Future Upside Potential
Analysts now estimate fair value for Healthpeak Properties at about US$20.17 per share, compared with roughly US$20.68 previously. The change reflects slightly revised assumptions around discount rates, long term revenue growth, profit margins and future P/E levels.ナラティブ更新 • Jan 19
DOC: Share Repurchases And Higher Future P/E Will Support Upside Potential
Analysts have nudged their price target on Healthpeak Properties slightly higher to about US$26.71 from roughly US$26.65, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. Together, these factors shape a modestly revised outlook for the shares.ナラティブ更新 • Jan 05
DOC: Completed Buyback And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to about US$20.68 per share from roughly US$20.92, citing slightly higher discount rate assumptions along with modest adjustments to revenue growth, profit margin, and future P/E inputs in their models. What's in the News From July 1, 2025 to September 30, 2025, Healthpeak Properties reported no share repurchases under its current program, with 0 shares bought for US$0 million in that period (Key Developments).ナラティブ更新 • Dec 14
DOC: Share Repurchases And Margin Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to approximately $26.65 from about $27.73, reflecting slightly higher discount-rate assumptions and more modest revenue growth expectations, partially offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Completed repurchase of 5,091,156 shares for approximately $94.17 million under the buyback program announced on July 25, 2024, representing about 0.73% of shares (Key Developments) No additional shares were repurchased between July 1, 2025 and September 30, 2025 under the existing buyback tranche, with total spending of $0 million in the period (Key Developments) Removed from the FTSE All-World Index (USD), which may affect index-linked ownership and trading volumes for the stock (Key Developments) Valuation Changes Fair Value Estimate decreased slightly to approximately $26.65 from about $27.73.ナラティブ更新 • Nov 30
DOC: Lower Discount Rate Will Support Improving Profit Margins Moving Forward
Analysts have modestly increased their price target for Healthpeak Properties from $20.86 to $20.92. This reflects slightly improved forward-looking profit margins and a lower discount rate, although it is partially tempered by a more conservative outlook for revenue growth.ナラティブ更新 • Nov 16
DOC: Discount Rate Improvements Will Drive Margin Gains Ahead
Analysts have slightly lowered their price target for Healthpeak Properties from $21.03 to $20.86. They cite modest adjustments in growth and discount rate assumptions, while also noting a marginal improvement in profit margins.ナラティブ更新 • Nov 01
DOC: Share Repurchase And Index Removal Will Unlock Future Upside Potential
Analysts have slightly lowered their price target for Healthpeak Properties to $21.03 from $21.19, citing modest reductions in revenue growth and profit margin expectations as key factors behind the revision. What's in the News Healthpeak Properties completed the repurchase of 5,091,156 shares, representing 0.73% of outstanding shares, for $94.17 million under its buyback announced on July 25, 2024 (Key Developments).ナラティブ更新 • Oct 17
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly lowered their price target for Healthpeak Properties from $21.31 to $21.19, citing a modest increase in expected discount rates and revenue growth, along with a small dip in projected profit margin. What's in the News Healthpeak Properties, Inc.ナラティブ更新 • Oct 03
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly revised their price target for Healthpeak Properties downward from $21.38 to $21.31. This change reflects minor updates to discount rate and valuation assumptions.ナラティブ更新 • Sep 17
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties' fair value estimate edged only slightly lower as both its future P/E ratio and net profit margin saw negligible declines, resulting in a marginal decrease in the consensus analyst price target from $21.53 to $21.38. What's in the News Lowered full-year 2025 diluted EPS guidance to $0.25–$0.31 from $0.30–$0.36.ナラティブ更新 • Sep 02
Outpatient And Life Science Trends Will Create Future Opportunities
The slight reduction in Healthpeak Properties’ future P/E ratio suggests a modestly improved earnings outlook relative to price, but with consensus revenue growth unchanged, analysts have only marginally decreased the fair value estimate from $21.72 to $21.53. What's in the News Healthpeak Properties lowered its full-year 2025 diluted EPS guidance to $0.25 – $0.31 from $0.30 – $0.36.ナラティブ更新 • Aug 19
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties’ fair value saw a marginal decrease as a slight drop in its future P/E multiple reflected modestly softer forward expectations. What's in the News Completed share repurchase program, buying 5,091,156 shares (0.73%) for $94.17 million.Seeking Alpha • Apr 10
Healthpeak Properties: Defensive REIT With Strong Dividend And Post-Merger Upside
Summary Healthpeak Properties is a high-quality healthcare REIT trading at a low valuation, offering 25-30% price appreciation and a ~6.7% annual dividend yield. The successful merger with Physicians Realty Trust has created a dominant healthcare REIT with significant synergies, improving operational performance and tenant diversification. Healthpeak's portfolio benefits from a strong demographic tailwind, robust leasing activity, and strategic focus on outpatient medical buildings and life science properties. Trading at a lower valuation than peers, Healthpeak's strong fundamentals make it an attractive buy for total return and income-focused investors. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Why Healthpeak Is A Smart Buy For Income Investors
Summary Healthpeak Properties offers a compelling investment opportunity with a 5.9% dividend yield, strong operating fundamentals, and an attractive valuation. DOC's diversified healthcare portfolio benefits from limited new supply, robust demand, and strategic loan investments in life sciences for immediate earnings accretion. With a strong balance sheet and a forward P/FFO of 11.2, DOC is well-positioned for long-term growth and potential market-beating returns. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
A REIT Geek Who Likes Healthpeak
Summary Healthpeak Properties is a top healthcare REIT with a robust portfolio, strong fundamentals, and a well-covered 6% yield, making it an attractive investment. Despite recent price declines, Healthpeak's AFFO growth, low leverage, and strategic life-science assets position it for stability and modest growth. The lab space market's tightening supply and increased biotech capital raise Healthpeak's valuation potential, justifying a conservative P/AFFO of 14-16x. At a share price of $16-$18, Healthpeak offers a compelling buy opportunity with an expected annualized return of 16-17%, supported by analyst consensus. Read the full article on Seeking AlphaSeeking Alpha • Dec 22
Healthpeak Properties: I'm Buying The 6% Dividend Yield
Summary Healthpeak Properties has dipped and now offers a 6% dividend yield that's 147% covered by its fiscal 2024 third-quarter FFO. The REIT generated free cash flow in excess of dividend payments during the third quarter. Spiking US 10-year Treasury yield forms a material headwind for stock price growth. Read the full article on Seeking AlphaSeeking Alpha • Oct 21
Healthpeak: Potential Upside Still Exists, But Don't Expect Much
Summary Healthpeak Properties is a BBB+ rated healthcare REIT with a solid portfolio, low leverage, and a well-covered 5.4% yield, offering a conservative 15% annualized return. The company is nearing full valuation but remains attractive due to its stable fundamentals, slight growth prospects, and recent merger benefits. Despite low growth estimates, Healthpeak's conservative P/AFFO of 14.25x suggests a potential upside, making it a "Buy" with a $27/share price target. Healthpeak fulfills all my investment criteria except being cheap, making it a sound investment for conservative, double-digit returns. Read the full article on Seeking Alpha
新しいナラティブ • Aug 21
Strategic Mergers And Key Life Science Leases Propel Revenue And Earnings Growth
Execution of priorities like merger integration and asset sales directly boosts 2024 guidance, signaling positive revenue and earnings impact.Seeking Alpha • Jul 18
Healthpeak: Missing The Boat Above $20/Share
Summary I update on investment in Healthpeak REIT, owning a significant stake with a positive return on investment and yield of over 7%. I highlight the undervaluation of Healthpeak, positive outlook on a diverse portfolio, and caution on current share price above $20. I maintain my thesis on Healthpeak as an attractive buy with conservative double-digit upside potential, based on sound fundamentals and future growth prospects. Read the full article on Seeking Alpha株主還元
| DOC | US Health Care REITs | US 市場 | |
|---|---|---|---|
| 7D | -5.1% | -0.2% | 2.2% |
| 1Y | 20.6% | 30.1% | 20.9% |
業界別リターン: DOC過去 1 年間で30.1 % の収益を上げたUS Health Care REITs業界を下回りました。
リターン対市場: DOCは、過去 1 年間で20.9 % のリターンをもたらしたUSマーケットと一致しました。
価格変動
| DOC volatility | |
|---|---|
| DOC Average Weekly Movement | 3.4% |
| Health Care REITs Industry Average Movement | 4.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: DOC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: DOCの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1985 | 411 | Scott Brinker | www.healthpeak.com |
Healthpeak Properties, Inc. は、完全統合型の不動産投資信託（REIT）であり、S&P 500 構成企業です。Healthpeak は、医療研究および医療提供のための高品質な不動産を所有、運営、開発しています。 Healthpeak Properties, Inc.は、コロラド州デンバーに本社を置いています。同社は1985年にメリーランド州で設立されました。
Healthpeak Properties, Inc. 基礎のまとめ
| DOC 基礎統計学 | |
|---|---|
| 時価総額 | US$14.68b |
| 収益（TTM） | US$242.74m |
| 売上高(TTM) | US$2.95b |
58.3x
PER（株価収益率4.8x
P/SレシオDOC は割高か？
公正価値と評価分析を参照収益と収入
| DOC 損益計算書（TTM） | |
|---|---|
| 収益 | US$2.95b |
| 売上原価 | US$1.25b |
| 売上総利益 | US$1.70b |
| その他の費用 | US$1.46b |
| 収益 | US$242.74m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.35 |
| グロス・マージン | 57.65% |
| 純利益率 | 8.23% |
| 有利子負債／自己資本比率 | 105.6% |
DOC の長期的なパフォーマンスは？
過去の実績と比較を見る| Healthpeak Properties 配当日 | |
|---|---|
| 配当落ち日 | Aug 17 2026 |
| 配当支払日 | Aug 28 2026 |
| 配当落ちまでの日数 | 5 days |
| 配当支払日までの日数 | 16 days |
DOC 配当は確実ですか？
DOC 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/11 21:53 |
| 終値 | 2026/08/11 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Healthpeak Properties, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。37
| アナリスト | 機関 |
|---|---|
| Jacob Kilstein | Argus Research Company |
| David Rodgers | Baird |
| Adam Feinstein | Barclays |